Evolocumab In Advanced Chronic Kidney Disease Trial
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
110 individuals with stage 4-5 Chronic Kidney Disease (CKD) will be randomized to 1-year of
blinded Evolocumab or placebo. Subjects will undergo evaluation of circulating lipids at
baseline and end of study. A substudy including 50 subjects will assess myocardial rest and
stress positron emission tomography (PET) at baseline and at 1-year.